Ocugen has reported preliminary phase 2 data on its eye disease gene therapy, providing more evidence that the candidate may ...

Treatment strategies for diabetic macular oedema (DME) have evolved over the past decade, with focal laser therapy being largely replaced by intravitreal injections, an observational case series of ...

Phase 2 (~50% of patients evaluated to date at 12 months) shows 46% lesion growth reduction vs. controlThere are no OCU410-related serious ...

The study found significant intra-group CMT reductions in the DEX-I group, with a higher percentage reduction than the ...

Christina Y. Weng, MD, MBA, and colleagues compared the intended treatment intervals with the actual follow-up intervals for patients treated with anti–vascular endothelial growth factor (VEGF) ...

Please provide your email address to receive an email when new articles are posted on . There are more options available than just the standard methods. Choices need to be made for every step of the ...

This prospective randomized clinical trial was approved by the Miami Veterans Affairs Medical Center Institutional Review Board and was HIPAA compliant. The study was registered with ClinicaTrials.gov ...

A novel treatment that uses a disintegrating matrix for sustained release of medication led to improvement in vision and reduced supplemental treatment in patients with diabetic macular edema, ...

Please provide your email address to receive an email when new articles are posted on . Intravitreal injections have a large environmental impact, estimated to be around 210 million kg of CO 2 ...

STOCKHOLM — Simple changes, like minimizing patient visits and reducing the use of nonsterile gloves, can make a big difference in the environmental impact of intravitreal injections without ...